Navigation Links
Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
Date:4/19/2011

SCHAUMBURG, Ill., April 20, 2011 /PRNewswire/ -- Sagent Pharmaceuticals (Nasdaq: SGNT) announced the upsizing and pricing of its initial public offering.  The size of the offering has been increased from the previously announced 5,000,000 shares of common stock to 5,750,000 shares of common stock at a price to the public of $16.00 per share. The shares are scheduled to begin trading on The NASDAQ Global Market on April 20, 2011 under the ticker symbol "SGNT."  The underwriters have a 30-day option to purchase up to an additional 862,500 shares at the initial public offering price. The offering is expected to close on April 26, 2011.

Morgan Stanley, BofA Merrill Lynch, and Jefferies are acting as the joint bookrunners for the offering. Needham & Company, LLC and RBC Capital Markets are acting as the co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 19, 2011. The offering is being made only by means of a prospectus, copies of which may be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by e-mail at prospectus@morganstanley.com; from BofA Merrill Lynch, 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department, or by e-mail at dg.prospectus_requests@baml.com; or from Jefferies, 520 Madison Avenue, 12th Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securit
'/>"/>

SOURCE Sagent Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
2. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
3. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
4. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
5. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
6. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
7. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
8. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
9. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
10. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
11. Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
(Date:11/26/2014)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce the ... and Consultancy focusing on the active pharmaceutical ingredient (API) ... visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s ... – Forecast to 2020 , IQ4I ...
(Date:11/26/2014)... Reinforcing its commitment to enabling confident diagnosis ... PHG AEX: PHIA) today announced 510(k) clearance from ... IQon Spectral CT , presenting an entirely new ... a new dimension to Computed Tomography (CT) imaging, delivering ... based on their material content within a single scan. ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3
... Tolerx, Inc. and GlaxoSmithKline (GSK) today ... an investigational humanized anti-CD3 monoclonal antibody, did not meet ... month 12 in patients with new-onset autoimmune type 1 ... data, no new or unexpected treatment-related safety concerns have ...
... MATEO, Calif., March 11, 2011 Sonitus Medical, Inc., ... non-surgical and removable hearing prosthetic to transmit sound via ... Mark certification for its SoundBite Hearing System. The company ... Assurance System Approval. This is the first European regulatory ...
Cached Medicine Technology:Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 2Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 3Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 4Sonitus Medical Receives European CE Mark for SoundBite™ Hearing System 2
(Date:11/28/2014)... Junk-A-Car ( http://www.junkacar.com ), one of the ... to help drivers, especially those in and around the ... areas deal with the especially harsh winter weather that ... the country. , With the high number of reported ... crashed and junk cars, Junk-A-Car is voluntarily ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Novatus, ... announced its Release v5.1 which provides customers with ... workflow options. , “As we continue to ... to provide more functionality and improved performance in ... Gambotz, CEO for Novatus. “With the enhancements that ...
(Date:11/28/2014)... November 28, 2014 Mirena lawsuits ... forward in New Jersey’s Bergen County Superior Court, ... litigation established there is quickly approaching 1,300, Bernstein ... November 18th shows 1,293 lawsuits now pending in ... that allege complications resulting from spontaneous migration of ...
(Date:11/28/2014)... Walder, one of South Florida’s top cosmetic dermatologists , ... that is designed to help her patients reduce unwanted fat ... has been praised by patients as being permanent, painless, and ... types of external fat reduction. , “If you can pinch ... According to Dr. Walder, Ultrashape works by targeting subcutaneous fat, ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded cosmetic ... Event for those in the area that would like to learn ... Glow will take place on December 11, 2014, from 6:00 p.m. ... of Houston at 4208 Richmond Ave. , “We want to ... come and celebrate the season with us on December 11, 2014 ...
Breaking Medicine News(10 mins):Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3
... Prenatal Solution Key Factor in Decision for ... Jan. 8 Allscripts announced today that ... multi-specialty group practices in the Southeast United ... Health Record (EHR) to automate and connect ...
... Hospital have demonstrated a more effective treatment for ... antibiotics clindamycin and azithromycin, which kill bacteria by ... a standard first-line treatment with the "beta-lactam" antibiotic ... burst. , The finding is important ...
... 8 Allscripts-Misys Healthcare,Solutions, Inc., formerly Allscripts Healthcare ... financial results for the three and six,months ended ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b ) , ... six months ended November 30, 2008,include results from ...
... 8 /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: CHDX ... of Western healthcare products and services in the People,s ... the 2009 UBS Greater,China Conference, to be held in ... The 2009 UBS Greater China Conference will ...
... should be used when assessing traditional risk factors, experts say ... -- or "biomarkers" -- of inflammation may provide useful information ... research says. , "If you are very high or very ... said study lead author Dr. Vijay Nambi, a cardiologist at ...
... business continues to drive overall performanceDALLAS, Jan. 8 ... leader in hosted services for email encryption and e-prescribing, ... officer, Rick Spurr."We ended the year on a high ... the highest orders for the year in the fourth ...
Cached Medicine News:Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 2Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 4
... Multimode Detectors provide unmatched value and ... and automation needs. Capable of performing ... the same instrument, the DTX Series ... can be integrated seamlessly with Beckman ...
... Screening (HTS), Analyst HT smoothes the ... sharing all the detection modalities and ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ... into robotic environments, including those from ...
... the right features for assay development ... instrument control. Reduces the inevitable transfer ... HTS. Specifically developed to meet the ... AD delivers unparalleled detection performance for ...
... a flexible multifunction plate reader that offers ... fluorescence intensity, time-resolved fluorescence, high-perfomance luminescence and ... with injectors that deliver reagent at the ... cell assays can be performed easily and ...
Medicine Products: